Q1 Earnings Estimate for ABEO Issued By Zacks Small Cap

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at Zacks Small Cap issued their Q1 2025 earnings per share estimates for shares of Abeona Therapeutics in a report issued on Monday, March 24th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings per share of ($0.34) for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q2 2025 earnings at ($0.33) EPS.

ABEO has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Oppenheimer started coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics has an average rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Stock Performance

ABEO stock opened at $4.99 on Wednesday. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45. The firm has a market cap of $216.92 million, a price-to-earnings ratio of -1.86 and a beta of 1.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The firm has a 50-day simple moving average of $5.43 and a two-hundred day simple moving average of $5.82.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently bought and sold shares of ABEO. Jane Street Group LLC purchased a new position in shares of Abeona Therapeutics in the third quarter worth $84,000. JPMorgan Chase & Co. increased its position in shares of Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 28,606 shares during the period. Western Standard LLC raised its stake in Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in Abeona Therapeutics during the 3rd quarter worth about $151,000. Finally, XTX Topco Ltd purchased a new stake in Abeona Therapeutics during the 3rd quarter valued at about $160,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.